Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma

doi:10.1016/j.ijrobp.2006.07.012

Title: Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma

Full Record
Similar

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) has been proven as an Epstein-Barr virus (EBV)-associated cancer. Serum anti-EBV antibodies and plasma EBV DNA have been investigated as surrogate markers for NPC. A comparison of the prognostic impacts of both assays has never been reported. Methods and Materials: Paired serum and plasma samples from 114 previously untreated NPC patients were collected and subjected to an immunofluorescence assay for immunoglobulin (Ig)A and IgG antibodies against the viral capsid antigen (VCA) and a real-time quantitative polymerase chain reaction assay for EBV DNA measurement. The effects of both assays on patient prognosis were thoroughly investigated. Results: Relapsed patients had significantly higher pretreatment EBV DNA concentration than patients without relapse (p 0.0006). No associations of VCA-IgA (p = 0.9669) or VCA-IgG (p = 0.6125) were observed between patients with and without relapse. The 4-year overall survival (60.3% vs. 93.1%, p < 0.0001) and relapse-free survival rates (54.4% vs. 77.9%, p = 0.0009) were significantly lower in patients with higher pretreatment EBV DNA load than in those with lower EBV DNA load. Patients with persistently detectable EBV DNA after treatment had significantly worse 4-year overall (30.8% vs. 84.6%, p < 0.0001) and relapse-free survival rates (15.4% vs. 74.0%, pmore »« less

Authors:

Twu, C.-W. ^[1]; Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung ^[2]; Wang, W.-Y. ^[3]; Liang, W.-M. ^[4]; Jan, J.-S. ^[5]; Jiang, R.-S. ^[6]; Chao, Jeffrey ^[5]; Jin, Y.-T. ^[7]; Lin, J.-C. ^[8]

Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (China)
(China)
Section of Basic Medicine, Department of Nursing, Hung Kuang University, Taichung (China)
Department of Public Health, China Medical University, Taichung (China)
Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung (China)
Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung (China)
Department of Pathology, National Cheng Kung University Hospital, Tainan (China)
Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (China) and Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung (China) and Department of Medicine, School of Medicine, China Medical University, Taichung, Taiwan (China). E-mail: jclin@vghtc.gov.tw

Publication Date:: Mon Jan 01 00:00:00 EST 2007

OSTI Identifier:: 20850305

Resource Type:: Journal Article

Resource Relation:: Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.07.012; PII: S0360-3016(06)01172-2; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIBODIES; ANTIGENS; CARCINOMAS; DNA; IMMUNOGLOBULINS; MULTIVARIATE ANALYSIS; ONCOGENIC VIRUSES; PATIENTS; POLYMERASE CHAIN REACTION

Citation Formats


                    Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., and Lin, J.-C. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.  United States: N. p., 2007. 
        Web.  doi:10.1016/j.ijrobp.2006.07.012.

Copy to clipboard


                    Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., & Lin, J.-C. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.  United States.  doi:10.1016/j.ijrobp.2006.07.012.

Copy to clipboard


                    Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., and Lin, J.-C. Mon .  
        "Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma".  United States.  
        doi:10.1016/j.ijrobp.2006.07.012.

Copy to clipboard


                    
@article{osti_20850305,

  title        = {Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma},

  author       = {Twu, C.-W. and Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung and Wang, W.-Y. and Liang, W.-M. and Jan, J.-S. and Jiang, R.-S. and Chao, Jeffrey and Jin, Y.-T. and Lin, J.-C.},

  abstractNote = {Purpose: Nasopharyngeal carcinoma (NPC) has been proven as an Epstein-Barr virus (EBV)-associated cancer. Serum anti-EBV antibodies and plasma EBV DNA have been investigated as surrogate markers for NPC. A comparison of the prognostic impacts of both assays has never been reported. Methods and Materials: Paired serum and plasma samples from 114 previously untreated NPC patients were collected and subjected to an immunofluorescence assay for immunoglobulin (Ig)A and IgG antibodies against the viral capsid antigen (VCA) and a real-time quantitative polymerase chain reaction assay for EBV DNA measurement. The effects of both assays on patient prognosis were thoroughly investigated. Results: Relapsed patients had significantly higher pretreatment EBV DNA concentration than patients without relapse (p 0.0006). No associations of VCA-IgA (p = 0.9669) or VCA-IgG (p = 0.6125) were observed between patients with and without relapse. The 4-year overall survival (60.3% vs. 93.1%, p < 0.0001) and relapse-free survival rates (54.4% vs. 77.9%, p = 0.0009) were significantly lower in patients with higher pretreatment EBV DNA load than in those with lower EBV DNA load. Patients with persistently detectable EBV DNA after treatment had significantly worse 4-year overall (30.8% vs. 84.6%, p < 0.0001) and relapse-free survival rates (15.4% vs. 74.0%, p < 0.0001) than those with undetectable EBV DNA. The VCA-IgA and VCA-IgG titer could not predict survivals (all p > 0.1). Cox multivariate analyses also showed the same results. Conclusion: Plasma EBV DNA is superior to serum EBV VCA antibodies in prognostic predictions for NPC.},

  doi          = {10.1016/j.ijrobp.2006.07.012},

  journal      = {International Journal of Radiation Oncology, Biology and Physics},

  number       = 1,

  volume       = 67,

  place        = {United States},

  year         = {Mon Jan 01 00:00:00 EST 2007},

  month        = {Mon Jan 01 00:00:00 EST 2007}

}

Copy to clipboard

Journal Article:

DOI: 10.1016/j.ijrobp.2006.07.012

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Demonstration of the serum antibody to Epstein-Barr virus specific DNA polymerased (EBV-DP) from patients with nasopharyngeal carcinoma (NPC)

Tan, R.S. ; Li, J.S. ; Grill, S. ; ... - Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)

Raji cells, an EBV genome carrying and nonproducer cell line, treated with tetradecanoyl-phorbol-13-acetate (TPA) and n-butyrate could induce a special DNA polymerase which has properties that are similar to the EBV-DP induced by TPA in P/sub 3/HR-I cells, an EBV producer cell line. Since EBV was found to have a strong association with NPC, and antibodies against EBV proteins or enzymes were found in high levels in sera from these patients, the possible presence of serum antibody against EBV-DP was examined. The serum titer of antibody to EBV-DP was found to have 190 +/- 84 units/ml serum (mean +/- S.D.)more »« less
Improved assays for DNA-polymerizing enzymes by the use of enzymatically synthesized 5-( sup 125 I)iodo-2'-deoxyuridine triphosphate, illustrated by direct quantitation of anti-HIV reverse transcriptase antibody and by serum DNA polymerase analyses

Neumueller, M.K. ; Karlstroem, A.R.K. ; Kaellander, C.F.G. ; ... - Biotechnology and Applied Biochemistry; (USA)

A one-step procedure which uses enzymes in a crude extract of herpes simplex virus (HSV) type 1-infected cells to synthesize 5-(125I)iodo-2'-deoxyuridine triphosphate (( 125I)dUTP) from (125I)dU is described. The design of a one-step procedure for the purification of the product is also presented. The recovery of (125I)dUTP from (125I)dU varied between 50 and 75%, the radiochemical purity of the product was greater than 90%, and both synthesis and purification were completed within 8 h. The sensitivity and specificity of (125I)dUTP as a substrate for both DNA-dependent DNA polymerase (DNAp) and RNA-dependent DNA polymerase (reverse transcriptase, RT) were evaluated and comparedmore »« less
INCREASE IN ANTIBODY TITER AGAINST THE EBV-ASSOCIATED MEMBRANE ANTIGEN COMPLEX IN BURKITT'S LYMPHOMA AND NASOPHARYNGEAL CARCINOMA AFTER LOCAL IRRADIATION.

Einhorn, N. ; Klein, G. ; Clifford, P. - Cancer 26: 1013-21(Nov 1970).
DOI: 10.1002/1097-0142(197011)26:5<1013::AID-CNCR2820260508>3.0.CO;2-N
Long-Term Prognostic Effects of Plasma Epstein-Barr Virus DNA by Minor Groove Binder-Probe Real-Time Quantitative PCR on Nasopharyngeal Carcinoma Patients Receiving Concurrent Chemoradiotherapy

Lin, J.-C. ; Wang, W.-Y. ; Liang, W.-M. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate the long-term prognostic impact of plasma Epstein-Barr virus (EBV) DNA concentration measured by real-time quantitative polymerase chain reaction (RTQ-PCR) in nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT). Methods and Materials: Epstein-Barr virus DNA was retrospectively measured from stock plasma of 152 biopsy-proven NPC patients with Stage II-IV (M0) disease with a RTQ-PCR using the minor groove binder-probe. All patients received CCRT with a median follow-up of 78 months. We divided patients into three subgroups: (1) low pretreatment EBV DNA (<1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-L/post-U) (2) high pretreatment EBV DNA ({>=}1,500 copies/mL) and undetectablemore »« less
DOI: 10.1016/j.ijrobp.2007.02.012
The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

Liu, Li-Ting ; Tang, Lin-Quan ; Chen, Qiu-Yan ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To explore the prognostic value of the plasma load of Epstein-Barr viral (EBV) DNA and the tumor response to neoadjuvant chemotherapy (NACT) in advanced-stage nasopharyngeal carcinoma (NPC). Patients and Methods: In all, 185 consecutive patients with stage III to IVb NPC treated with NACT followed by concurrent chemoradiation therapy (CCRT) were prospectively enrolled. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included locoregional relapse–free survival (LRFS) and distant metastasis–free survival (DMFS). Results: EBV DNA was detected in 165 (89%) patients before treatment but was undetectable in 127 (69%) patients after NACT. Detectable EBV DNA levels aftermore »« less
DOI: 10.1016/J.IJROBP.2015.08.003